CRDF GLOBAL WILL PROVIDE FIDUCIARY SUPPORT TO CDC TO MANAGE TB-RELATED ACTIVITIES

CRDF全球CDC-RFA-PS11 - 1111 国际旅行者和外国出生的人口。支持建筑物检疫和 移民保健系统。 14.8）促进实现为2015年设定的减轻结核病负担的全球目标 在千年发展目标和世界卫生组织的框架内 世卫组织控制结核伙伴关系：停止并开始扭转 到2015年将结核病发病率和死亡率降低50% 与1990年的水平相比。 14.9.支持全球卫生倡议，包括全球卫生倡议+国家。的 该倡议的核心原则强调国家所有权;性别平等方法; 以及融合，协调，创新等主题。 二.需求描述 所列的需求说明是关于将要实施的各个项目的， 如下 项目1：基于DNA的M.结核病和相关的基因突变 可能为迅速扩大实验室检测能力提供最佳选择， M.在中低收入国家，结核病和耐药结核病的诊断。不同 这些技术已投入商业使用，而且正在开发更多的技术。结核病控制计划 低收入和中等收入国家在实施这些技术方面需要技术援助 用于结核病的诊断和管理。这些方案活动的结果将指导 未来的政策和做法，以扩大和适应新的诊断技术， 变得可用。 2011年CRDF全球专有和机密

CRDF Global CDC-RFA-PS11-1111 international travelers and foreign born populations. Support in building quarantine and migration health systems. 14.8) Contribute to the global targets for reducing the burden of TB that have been set for 2015 within the context of the Millennium Development Goal and by the World Health Organization's (WHO) Stop TB Partnership: Halt and begin to reverse the incidence of tuberculosis (TB) by 2015 and reduce by 50% TB prevalence and death rates by 2015 compared with their levels in 1990. 14.9) Provide support to the Global Health Initiative (GHI), including GHI Plus countries. The core principles of the initiative emphasize country ownership; a gender-equity approach; and integration, coordination, and innovation, among other themes. II. Description of Need Statements of need are listed with regard to the individual projects to be implemented, as follows. Project 1: DNA-based diagnostic tests for M. tuberculosis and genetic mutations associated with drug resistance may offer the best option for rapidly scaling up laboratory capacity to detect M. tuberculosis and diagnose drug-resistant TB in middle- and low-income countries. Different technologies are commercially available and more are being developed. TB Control Programs in low and middle income countries need technical assistance in implementing these technologies for the diagnosis and management of TB. The results of these programmatic activities will guide future policy and practice for expanding and adapting new diagnostic technologies as they become available. 2011 CRDF Global Proprietary and Confidential